ATE214274T1 - Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose - Google Patents

Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose

Info

Publication number
ATE214274T1
ATE214274T1 AT97931367T AT97931367T ATE214274T1 AT E214274 T1 ATE214274 T1 AT E214274T1 AT 97931367 T AT97931367 T AT 97931367T AT 97931367 T AT97931367 T AT 97931367T AT E214274 T1 ATE214274 T1 AT E214274T1
Authority
AT
Austria
Prior art keywords
anticonvulsivals
treatment
lateral sclerosis
amyotropic lateral
amyotropic
Prior art date
Application number
AT97931367T
Other languages
English (en)
Inventor
Richard P Shank
Original Assignee
Ortho Mcneil Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Corp Inc filed Critical Ortho Mcneil Corp Inc
Application granted granted Critical
Publication of ATE214274T1 publication Critical patent/ATE214274T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
AT97931367T 1996-06-28 1997-06-24 Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose ATE214274T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2200696P 1996-06-28 1996-06-28
PCT/US1997/010955 WO1998000131A1 (en) 1996-06-28 1997-06-24 Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (als)

Publications (1)

Publication Number Publication Date
ATE214274T1 true ATE214274T1 (de) 2002-03-15

Family

ID=21807346

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97931367T ATE214274T1 (de) 1996-06-28 1997-06-24 Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose

Country Status (22)

Country Link
US (1) US5753694A (de)
EP (1) EP0936908B1 (de)
JP (1) JP2000514426A (de)
AP (1) AP1167A (de)
AT (1) ATE214274T1 (de)
AU (1) AU725093B2 (de)
BR (1) BR9710993A (de)
CA (1) CA2258892C (de)
CZ (1) CZ293945B6 (de)
DE (1) DE69711067T2 (de)
DK (1) DK0936908T3 (de)
ES (1) ES2176755T3 (de)
HU (1) HUP9904318A3 (de)
IL (1) IL127717A (de)
NO (1) NO317136B1 (de)
NZ (1) NZ333588A (de)
PT (1) PT936908E (de)
SI (1) SI0936908T1 (de)
SK (1) SK284331B6 (de)
UA (1) UA46112C2 (de)
WO (1) WO1998000131A1 (de)
ZA (1) ZA975764B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
WO2000061138A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
ES2542868T3 (es) 1999-06-14 2015-08-12 Vivus, Inc. Terapia de combinación para el tratamiento de diabetes asociada con la obesidad
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US20020082222A1 (en) 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
DK1471871T3 (da) * 2001-02-02 2007-09-17 Ortho Mcneil Pharm Inc Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin
JP2005514352A (ja) * 2001-11-14 2005-05-19 ラルフ ライバック 自己免疫疾患の治療法
CA2505514A1 (en) * 2002-11-06 2004-05-27 Mount Sinai School Of Medicine Treatment of amyotrophic lateral sclerosis with nimesulide
US20060041022A1 (en) * 2002-11-06 2006-02-23 Pasinetti Giulio M Treatment of amyotrophic lateral sclerosis with nimesulide
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ES2310366T3 (es) * 2004-08-24 2009-01-01 Janssen Pharmaceutica Nv Nuevos derivados de heteroaril sulfonamida benzo-condensada utiles como agentes anticonvulsivos.
IS7748A (is) * 2005-03-17 2006-09-18 Actavis Group Samsetning fyrir töflur sem innihalda topiramate
JP2008545650A (ja) * 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
EP2026790A2 (de) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Kombinationstherapie zur behandlung von epilepsie und assoziierten erkrankungen
FR2903019A1 (fr) * 2006-06-30 2008-01-04 Univ Claude Bernard Lyon I Eta Utilisation d'un inhibiteur de l'anhydrase carbonique, pour la preparation d'un medicament destine a traiter des degenerescences du muscle squelettique
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates

Also Published As

Publication number Publication date
CZ427998A3 (cs) 1999-08-11
ZA975764B (en) 1998-12-28
SI0936908T1 (en) 2002-12-31
CA2258892C (en) 2005-08-09
UA46112C2 (uk) 2002-05-15
IL127717A0 (en) 1999-10-28
DK0936908T3 (da) 2002-05-27
AU3501097A (en) 1998-01-21
AP1167A (en) 2003-06-30
NO317136B1 (no) 2004-08-23
AP9801428A0 (en) 1998-12-31
ES2176755T3 (es) 2002-12-01
NZ333588A (en) 2000-07-28
SK180698A3 (en) 2000-07-11
SK284331B6 (sk) 2005-01-03
BR9710993A (pt) 2002-02-26
DE69711067T2 (de) 2002-09-19
US5753694A (en) 1998-05-19
NO986054D0 (no) 1998-12-22
IL127717A (en) 2004-09-27
EP0936908A1 (de) 1999-08-25
DE69711067D1 (de) 2002-04-18
HUP9904318A3 (en) 2001-02-28
AU725093B2 (en) 2000-10-05
CA2258892A1 (en) 1998-01-08
CZ293945B6 (cs) 2004-08-18
JP2000514426A (ja) 2000-10-31
PT936908E (pt) 2002-08-30
WO1998000131A1 (en) 1998-01-08
HUP9904318A2 (hu) 2000-05-28
NO986054L (no) 1999-03-01
EP0936908B1 (de) 2002-03-13

Similar Documents

Publication Publication Date Title
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
ATA46794A (de) Einrichtung zur behandlung von hautzonen
DE69528011D1 (de) Verfahren zur Pflege der Nägel
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
ATE278400T1 (de) Zusammensetzungen für die verwendung bei der behandlung und prävention von hyperurikämie
EP0709090A3 (de) Zusammensetzungen zur Behandlung von resistenten Tumoren
DE69714828D1 (de) Verfahren zur Behandlung von Abfallstoffen
DE69115921D1 (de) Verfahren zur behandlung und verwendung von abfallstoffen
ATE227278T1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE59705697D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE69701458D1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE60041365D1 (de) Verwendung von Riluzol zur Behandlung Multipler Sklerose
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee